Patient Advocacy

New studies from 23andMe suggest genetic variation may modestly influence GLP-1 weight-loss response and side effects.

A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.

The importance of aligning cost control with clinical appropriateness and continuity of care.

Jeanne Marrazzo, MD, FIDSA, MPH, CEO of the Infectious Diseases Society of America discusses the growing measles outbreak in the United States, which has surpassed 730 cases and represents the largest surge in decades.

A nationally representative survey of more than 20,000 U.S. adults found that 33% made at least one daily spending trade-off to pay for healthcare in the past year

Testing reveals that compounded tirzepatide products mixed with vitamin B12 contain a chemical impurity of unknown toxicity.

Public Citizen’s lawsuit highlights broader concerns over government transparency and oversight in pharmaceutical policy.

Both the AAP and CDC released their respective childhood vaccine guidance’s, including different vaccine administration recommendations, age limits, and combined vaccines.

Catalyst’s executive director of patient advocacy discusses the company’s new undergraduate program that provides participants with real-world experience in advocacy.

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as a critical, science-backed complement to GLP-1 weight-loss therapies.

Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing menopause and improving their health options.

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction issues.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a part.

Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.